CSL's Financial Results
CSL's Half Year financial results were announced on Wednesday, 12th February 2020. Please click the link below to view our historic Full Year and Half Year Financial Results.More Information
Search Results121 results found
CSL Limited Paul Perreault, CEO and MD 2020 Half Year Results David Lamont, CFO 12 February 2020 LEGAL NOTICE Forward looking st...
CSL Limited Paul Perreault, CEO and MD 2020 Half Year Results David Lamont, CFO 12 February 2020 LEGAL NOTICE Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL.
CSL Limited is a global biotechnology manufacturer that researches, develops, and markets products to treat and prevent rare and serious diseases. Learn more.
We will announced our 2020 Half Year Results on Wednesday, 12th February 2020 (AEDT)
CSL's exceptionally strong performance is a result of the focused execution of our strategy. Learn more.
12 February 2020 CSL Delivers a Strong Half Year Result1 Full Year profit guidance upgraded
US$0.93 per share, unfranked, paid on 12 October 2018 for FY18) Dividends determined, but not yet paid at the end of the half-year 431.2 386.5 Interim dividend of US$0.95 per share, unfranked, expected to be paid on 9 April 2020.
1 Chairman and CEO's Letter 2 CSL Calendar 2 2019 Performance 4 2019 Business performance and highlights 4 14 August Annual profi t and fi nal dividend announcement Financial highlights 5 10 September Shares traded ex-dividend 3 Our Company 6 11 September Record date for fi nal dividend Our businesses 6 Our locations 7 11 October Final dividend paid Our product portfolio 8 16 October Annual General Meeting Our research and development pipeline 9 31 December Half year ends 4 CSL Strategy 10 2020 How we create value 12 12 February Half year profi t and interim dividend 5 Powered by Innovation 14 announcement Collaboration with and funding of medical research 14 11 March Shares traded ex-dividend Investment in research and development pipeline 14 12 March Record date for interim dividend Focus on selected therapeutic areas - specialisation 15 9 April Interim dividend paid New products to market 16 30 June Year ends Clinical trials in process and new 18 19 August Annual profi t and fi nal dividend announcement Clinical trial transparency 18 10 September Shares traded ex-dividend Leveraging advanced analytics and artifi cial intelligence 19 11 September Record date for fi nal dividend Innovation across the value chain 19 9 October Final dividend paid 6 Global Reach and Impact 21 14 October Annual General Meeting Global reach and focus 21 31 December Half year ends Donor management 24 Focus on effi ciency, standardised manufacturing 24 processes and integrated supply chain Annual General Meeting Environment health and safety 25 Wednesday, 16 October 2019 at 1 p.m. Supply chain management 25 7 A Trusted Health Partner 26 New city and venue Product quality and safety 26 Value and access 27 The Westin Sydney, Grand Ballroom Public policy engagement 28 1 Martin Place Secure and reliable supply 29 Sydney NSW 2000 Pandemic and emergency response 29 Relationships with healthcare professionals 29 Share Registry regulators and patient groups Computershare Investor Services Pty Limited Responsible marketing and promotion 29 Postal Address:
We have now completed Phase 1 for CSL346 with planning underway for Phase 2a Proof of Concept study in patients with diabetic nephropathy to be initiated in the first half of next year. •
The PSUs and RSUs will become For the half year ended 31 December 2017, the Group has received gross proceeds exercisable on 1 September in each of 2018, 2019, 2020 and 2021, this is one month from borrowings of $1,140.9m comprising $700m from a new US private placement earlier than the anniversary of the date of grant, future grants will be made on 1 debt facility and $440.9m from the Group's bank facilities.